Mouse Von Willebrand Factor A2 ELISA Kit (RMEK-0154023)
Cat. No.: RMEK-0154023
Category: ELISA Kits
INQUIRY
1 x 96 tests
Mouse Von Willebrand Factor A2 ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Von Willebrand Factor A2 protein in cit plasma, edta plasma, hep plasma, serum, and cell culture supernatant. The technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time.
Product Features
| Species Reactivity | Mouse |
|---|---|
| Detection Method | Colorimetric |
| Assay Duration | One step assay |
| Assay Time | 1.5 h |
| Assay Type | Sandwich (quantitative) |
| Precision | Intra-Assay-Mouse plasma-5-5.3%; Inter-Assay-Mouse plasma-3-13.3% |
| Sensitivity | 37 pg/mL |
| Range | 109.38 pg/mL - 7000 pg/mL |
| Sample Type | Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum |
| Recovery | Serum-83.6-80.2% - 89.7%; Hep Plasma-82.2-78.8% - 86.7%; EDTA Plasma-94.4-88.2% - 98.3%; Cit plasma-86.3-82.7% - 90.3%; serum free media-79-70.9% - 83.8% |
| Key Features | One-wash 90 minute protocol; Sensitivity: 37 pg/mL; Range: 109.38 pg/mL - 7000 pg/mL; Sample type: Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Mouse |
Target Information
| Target Symbol | Vwf |
|---|---|
| UniProt ID | P04275 |
| Biomarker of SCs/CSCs | Triple Negative Breast Cancer |
| Function | Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. |
| Cellular Localization | Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules. |
| Domain | The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules. |
| Post-transcriptional Modifications | All cysteine residues are involved in intrachain or interchain disulfide bonds.N- and O-glycosylated. |
| Involvement in Disease | Defects in VWF are the cause of von Willebrand disease (VWD). VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. |
Storage & Shipping
| Storage | Store at 2-8°C |
|---|---|
| Shipping | Gel Packs |
| Stability | The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. |
For research use only. Not for clinical use.
